Literature DB >> 18606888

Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease.

Adam J Mead, Rosemary E Gale, Robert K Hills, Manu Gupta, Bryan D Young, Alan K Burnett, David C Linch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18606888     DOI： 10.1182/blood-2008-02-140392

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  12 in total

1.  Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.

Authors:  Aref Al-Kali; Jorge Cortes; Stefan Faderl; Dan Jones; Caroline Abril; Sherry Pierce; Mark Brandt; Hagop Kantarjian; Farhad Ravandi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-08

2.  Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.

Authors:  Talha Badar; Hagop M Kantarjian; Graciela M Nogueras-Gonzalez; Gautam Borthakur; Guillermo Garcia Manero; Michael Andreeff; Marina Konopleva; Tapan M Kadia; Naval Daver; William G Wierda; Raja Luthra; Keyur Patel; Betul Oran; Richard Champlin; Farhad Ravandi; Jorge E Cortes
Journal:  Am J Hematol       Date:  2015-09-10       Impact factor: 10.047

Review 3.  What Is the Optimal Induction Therapy for Younger Fit Patients With AML?

Authors:  Hugo F Fernandez
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

4.  Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Authors:  Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

5.  Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Authors:  Nicolas Duployez; Alice Marceau-Renaut; Nicolas Boissel; Arnaud Petit; Maxime Bucci; Sandrine Geffroy; Hélène Lapillonne; Aline Renneville; Christine Ragu; Martin Figeac; Karine Celli-Lebras; Catherine Lacombe; Jean-Baptiste Micol; Omar Abdel-Wahab; Pascale Cornillet; Norbert Ifrah; Hervé Dombret; Guy Leverger; Eric Jourdan; Claude Preudhomme
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

6.  Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.

Authors:  Maria Teresa Voso; Richard A Larson; Dan Jones; Guido Marcucci; Thomas Prior; Jürgen Krauter; Michael Heuser; Serena Lavorgna; Josep Nomdedeu; Susan M Geyer; Alison Walker; Andrew H Wei; Jorge Sierra; Miguel A Sanz; Joseph M Brandwein; Theo M de Witte; Joop H Jansen; Dietger Niederwieser; Frederick R Appelbaum; Bruno C Medeiros; Martin S Tallman; Richard F Schlenk; Arnold Ganser; Sergio Amadori; Yuan Cheng; YinMiao Chen; Celine Pallaud; Ling Du; Alfonso Piciocchi; Gerhard Ehninger; John Byrd; Christian Thiede; Konstanze Döhner; Richard M Stone; Hartmut Döhner; Clara D Bloomfield; Francesco Lo-Coco
Journal:  Blood Adv       Date:  2020-10-13

7.  The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial.

Authors:  M Lazenby; A F Gilkes; C Marrin; A Evans; R K Hills; A K Burnett
Journal:  Leukemia       Date:  2014-02-27       Impact factor: 11.528

8.  Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.

Authors:  Farhad Ravandi; Hagop Kantarjian; Stefan Faderl; Guillermo Garcia-Manero; Susan O'Brien; Charles Koller; Sherry Pierce; Mark Brandt; Deborah Kennedy; Jorge Cortes; Miloslav Beran
Journal:  Leuk Res       Date:  2009-10-29       Impact factor: 3.156

Review 9.  Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.

Authors:  Elias Jabbour; Jorge Cortes; Farhad Ravandi; Susan O'Brien; Hagop Kantarjian
Journal:  Semin Hematol       Date:  2013-10-03       Impact factor: 3.851

10.  Prognostic significance of the FLT3 ITD mutation in patients with normal-karyotype acute myeloid leukemia in relapse.

Authors:  Sang Hyuk Park; Hyun-Sook Chi; Sook-Kyung Min; Young-Uk Cho; Seongsoo Jang; Chan-Jeoung Park; Jung-Hee Lee; Je-Hwan Lee; Kyoo-Hyung Lee; Ho-Joon Im; Jong-Jin Seo
Journal:  Korean J Hematol       Date:  2011-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.